Latest Health News

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

SHAPE Australia has agreed to acquire Arden Group, expanding its footprint in retail fitout and facilities maintenance with an earnings accretive deal.

Control Bionics has integrated Apple’s Brain-Computer Interface protocol into its NeuroNode products, promising simpler setup and enhanced communication for users with severe impairments.

Monash IVF Group has appointed Dr Victoria Atkinson as its new Managing Director and CEO, effective May 2026, signaling a strategic leadership shift for the assisted reproductive services provider.

Scentre Group reports rising customer visits and strong sales growth across its Westfield portfolio, while confirming its 2025 earnings and distribution targets.

Scentre Group reports a 3.1% rise in customer visits and a $29.5 billion sales tally across its Westfield centres, while confirming its 2025 earnings and distribution targets.

Scentre Group reports a solid operating update for 2025, highlighting increased customer visits, rising business partner sales, and near-full occupancy across its Westfield centres.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

Etherstack plc reports a record-breaking FY25 with revenues up 62%, driven by major US and UK contracts, and projects continued strong growth into FY26 and beyond.

Bendigo and Adelaide Bank’s latest Basel III disclosures reveal a slight dip in capital ratios offset by improved liquidity and funding stability for the quarter ended September 2025.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.